Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Santen files application for approval of glaucoma and ocular hypertension drug

Santen Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, has filed an application for approval of manufacturing and marketing of the glaucoma and ocular hypertension therapeutic, COSOPT Mini Combination Ophthalmic Solution, in Japan.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

BELLUS Health Q2 net loss decreases

BELLUS Health Inc., a drug development company focused on rare diseases, has reported that net loss attributable to shareholders for the second quarter ended June 30, 2014 was C$737,000, or C$0.02 loss per share, compared to a net loss attributable to shareholders of C$867,000, or C$0.02 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

Aastrom Biosciences Q2 net loss down

Aastrom Biosciences, Inc. has reported a net loss of $4.64 million, or $0.94 loss per share, for the second quarter ended June 30, 2014, compared to a net loss of $4.89 million, or $2.72 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

Analytik Jena reports higher Q3 net loss, provides outlook for Q4

Analytik Jena AG has reported that net loss attributable to the shareholders of the parent company for the third quarter ended June 30, 2014 was E1.61 million, or E0.21 loss per share, compared to a net loss attributable to the shareholders of the parent company of E901,000, or E0.16 loss per share, for the same quarter ended June 30, 2013. The company expects operating profit of E3 million for the fourth quarter of 2014.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

ProMetic Life Sciences reports net profit for Q2

ProMetic Life Sciences Inc., a biopharmaceutical company, has reported a net profit attributable to the owners of the parent of C$23.96 million, or C$0.04 per diluted share, for the second quarter ended June 30, 2014, compared to a net loss attributable to the owners of the parent of C$2.45 million, or C$0.01 loss per diluted share, for the same quarter ended June 30, 2013.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

GE Healthcare introduces new ultrasound tool with dual probe

GE Healthcare, a provider of medical technologies and services, has introduced the next generation ultrasound tool, the Vscan with Dual Probe.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

PhysIOL enters into settlement agreement with Carl Zeiss Meditec

PhysIOL SA and Carl Zeiss Meditec AG, a medical technology company, have entered into an agreement to settle their legal dispute regarding patents and utility models for trifocal intraocular lenses, or IOL.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

Biostar Pharmaceuticals reports net income for Q2

Biostar Pharmaceuticals, Inc., a manufacturer of pharmaceutical and health supplement products, has reported a net income of $1.64 million, or $0.11 per share, for the second quarter ended June 30, 2014, compared to a net loss of $730,980, or $0.06 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

M*Modal expands medical transcription operations in Mysore, Karnataka

M*Modal, a provider of clinical documentation services and speech understanding solutions, has expanded its existing facility in Mysore, Karnataka.

Published By MarketLine
01 Sep 2014
NewsWire
NewsWire

Cook Medical initiates recall of 696 vascular retrieval snare devices

Cook Medical, a medical device company, has initiated a recall of 696 CloverSnare 4-Loop vascular retrieval snare devices.

Published By MarketLine
01 Sep 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.